Simcere and G1 Therapeutics announce the signing of an exclusive license agreement for Trilaciclib products in the Greater China region

On August 3, 2020 Simcere Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Simcere") and tumor clinical stage company G1 Therapeutics Company ( Nasdaq: GTHX ), reported the signing of an exclusive license to introduce Trilaciclib ‘s development and commercialization rights for all indications in Greater China (Mainland China, Hong Kong, Macau and Taiwan) (Press release, Jiangsu Simcere Pharmaceutical Company, AUG 3, 2020, View Source [SID1234562741]). Trilaciclib is the world’s first innovative drug discovered and developed by G1 to improve the prognosis of cancer patients after chemotherapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

" Trilaciclib may become the first prophylactically administered bone marrow protective therapy, which can effectively improve the prognosis of patients undergoing chemotherapy. We are very pleased to cooperate with Simcere , a Chinese company with leading innovative drug development and commercialization capabilities. , To promote this innovative therapy in China," said G1 CEO and MD Dr. Mark Velleca . "Sincere Pharmaceuticals has extensive experience in drug clinical trials and drug registration in China, and has a nationwide professional team that supports product academic promotion and market access. These advantages make them an important strategic partner of G1 to realize our The vision of bringing Trilaciclib to patients around the world."

According to the terms of the agreement, G1 will receive a down payment of US$ 14 million, and will receive development and commercialization milestone payments of up to US$ 156 million. Simultaneously, Simcere Pharmaceuticals will pay G1 low double-digit sales commission based on Trilaciclib ‘s annual net sales in Greater China . Simcere Pharmaceuticals will have the exclusive rights to develop and commercialize Trilaciclib for all indications in Greater China, and will participate in Trilaciclib ‘s global clinical trials. G1 reserves the right to develop and commercialize Trilaciclib in all regions outside the Greater China region. Both parties will be responsible for all development and commercialization costs in their respective regions.

Dr. Wang Pin, Chief Scientific Officer of Simcere Pharmaceuticals, said: "Currently, chemotherapy is the cornerstone therapy for cancer patients. A large number of patients in China are suffering from bone marrow suppression caused by chemotherapy. We are very pleased to have a deep cooperation with G1 Therapeutics in China. Developed and commercialized Trilaciclib , the world’s first product of its kind to protect bone marrow . We look forward to further expanding its clinical value based on Trilaciclib’s unique mechanism. We hope that through the joint efforts of both parties, Trilaciclib can benefit more cancer patients around the world as soon as possible."

Lung cancer is the most common cancer in the world, and small cell lung cancer accounts for about 15% of all lung cancer cases . According to statistics from the International Agency for Research on Cancer ( IARC ), a specialized cancer agency of the World Health Organization ( WHO ) , nearly 750,000 new lung cancer cases were reported in China in 2018 .

About Trilaciclib

Trilaciclib is the world’s first innovative product of its kind designed to improve the prognosis of cancer patients with chemotherapy. Trilaciclib is given before chemotherapy in patients with small cell lung cancer ( SCLC ). Based on the bone marrow protection data of three randomized, double-blind, placebo-controlled clinical trials in the United States, it has obtained FDA breakthrough therapy designation. In a randomized trial of patients with metastatic triple-negative breast cancer, compared with chemotherapy alone, trilaciclib when used in combination with chemotherapy significantly improved the overall survival of the patient. In 2020 Nian 6 Yue, G1 in the United States submitted a new drug application ( NDA ), is used to protect the bone marrow of patients with small cell lung cancer, and as I-Spy2 part of a pilot study began neoadjuvant chemotherapy. G1 expects to initiate a Phase III registered clinical trial for colorectal cancer in the United States in the fourth quarter of 2020 .

Entry into a Material Definitive Agreement

On August 3, 2020, Achieve Life Sciences, Inc. ("Achieve") reported that it entered into an underwriting agreement (the "Underwriting Agreement") with Lake Street Capital Markets, LLC (the "Underwriter"), pursuant to which Achieve agreed to issue and sell an aggregate of (a) 476,187 shares of its common stock (the "Shares") and (b) pre-funded warrants to purchase 142,857 shares of its common stock (the "Pre-Funded Warrants") to the Underwriters (the "Offering") (Filing, 8-K, OncoGenex Pharmaceuticals, AUG 3, 2020, View Source [SID1234562863]). The Shares will be sold at the public offering price of $10.50 per share. The Pre-Funded Warrants will be sold at a public offering price of $10.499 per Pre-Funded Warrant, which represents the per share public offering price for the Shares less a $0.001 per share exercise price for each such Pre-Funded Warrant. Pursuant to the Underwriting Agreement, Achieve has also granted the Underwriters a 30-day option to purchase up to an additional 92,856 shares of its common stock. The Underwriting Agreement contains customary representations and warranties, conditions to closing, termination provisions and indemnification obligations, including for liabilities under the Securities Act of 1933, as amended. The Offering is being made pursuant to the shelf registration statement on Form S-3 (File No. 333-229019) that was filed by Achieve with the Securities and Exchange Commission ("SEC") on December 26, 2018, and declared effective by the SEC on February 11, 2019, and a related prospectus supplement.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Pre-Funded Warrants are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. A holder of Pre-Funded Warrants may increase or decrease this percentage, but not in excess of 19.99%, by providing at least 61 days’ prior notice to Achieve.

Achieve estimates that net proceeds from the Offering will be approximately $5.9 million, after deducting underwriting discounts and commissions and estimated Offering expenses, and assuming no exercise of the Underwriters’ option to purchase additional shares. Achieve intends to use the net proceeds from the Offering, together with its existing cash, cash equivalents and marketable securities, to fund clinical research and development, and for general working capital. Achieve expects the Offering to close on August 6, 2020, subject to the satisfaction of customary closing conditions.

The Underwriting Agreement is filed as Exhibit 1.1 to this report and the foregoing description of the terms of the Underwriting Agreement is qualified in its entirety by reference to such exhibit. The Pre-Funded Warrant is filed as Exhibit 4.1 to this report and the foregoing description of the terms of the Pre-Funded Warrants is qualified in its entirety by reference to such exhibit. A copy of the opinion of Fenwick & West LLP, relating to the validity of the securities offered in connection with the Offering, is filed with this Current Report on Form 8-K as Exhibit 5.1.

Pieris Pharmaceuticals to Host Second Quarter 2020 Investor Call and Corporate Update on August 10, 2020

On August 3, 2020 Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases, cancer and other indications, reported that it will host a second quarter 2020 investor call on Monday, August 10, 2020 at 8:00 AM EDT to discuss financial results and provide a corporate update (Press release, Pieris Pharmaceuticals, AUG 3, 2020, View Source [SID1234562685]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the call, participants may dial 877-407-8920 (Toll Free US & Canada) or 412-902-1010 (International) at least 10 minutes prior to the start of the call.

An archived replay of the call will be available for 30 days by dialing 877-660-6853 (Toll Free US & Canada) or 201-612-7415 (International) and providing the Conference ID #13661472.

Salarius Announces Pricing of $5.3 Million Underwritten Public Offering

On August 3, 2020 Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, reported the pricing of an underwritten public offering of 4,461,209 shares of its common stock at a price to the public of $1.20 per share (Press release, Salarius Pharmaceuticals, AUG 3, 2020, View Source [SID1234562704]). All of the shares are being sold by Salarius. The gross proceeds to Salarius from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $5.3 million. The closing of the offering is expected to take place on or about August 3, 2020, subject to the satisfaction or waiver of customary closing conditions. In addition, Salarius has granted the underwriter a 45-day option to purchase up to 669,181 additional shares of common stock at the public offering price per share, less underwriting discounts and commissions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager in connection with the public offering.

The securities were offered pursuant to a registration statement on Form S-3 (File No. 333-231010), which was declared effective by the United States Securities and Exchange Commission (the "SEC") on May 17, 2019. When available, copies of the final prospectus supplement and accompanying prospectus relating to the offering can be obtained at the SEC’s website at www.sec.gov or from Ladenburg Thalmann & Co. Inc., Attn: Prospectus Department, 277 Park Avenue, 26th Floor, New York, New York 10172, by calling (212) 409-2000.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Personalis, Inc. Launches NeXT Liquid Biopsy™, A High-Performance, Exome-Wide Liquid Biopsy Platform

On August 3, 2020 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, reported the launch of NeXT Liquid Biopsy, a high-performance, exome-scale, tumor-profiling platform that utilizes blood samples from advanced-stage solid tumor cancer patients (Press release, Personalis, AUG 3, 2020, View Source [SID1234562723]). NeXT Liquid Biopsy, paired with Personalis’ leading ImmunoID NeXT tissue profiling platform, enables a more comprehensive immuno-genomics view of the tumor that can now be monitored over time from blood samples. NeXT Liquid Biopsy monitors over twenty times more genes than the majority of liquid biopsy cancer panels on the market today. These capabilities will help biopharmaceutical companies advance their understanding of tumor biology, including resistance mechanisms, to aid the development of next-generation cancer therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Personalis CEO, John West, said, "Solid tumor biopsies and liquid biopsies complement each other, and it is important to utilize both in cancer research. Solid tumor biopsies can yield information about mutations, gene expression, the tumor microenvironment, and immune cells that have infiltrated the tumor, while liquid biopsies can track mutations and detect new mutations over time in response to treatment. By combining NeXT Liquid Biopsy with ImmunoID NeXT, researchers now have a powerful tool to address tumor heterogeneity, longitudinally monitor clonal and subclonal dynamics, identify acquired resistance mechanisms, and access key areas of tumor biology not typically included in targeted liquid biopsy panels. We strongly believe this will provide a powerful framework for translational research, and the development of next-generation cancer therapeutics to overcome therapy resistance and cancer progression."

Mr. West added, "Through our collaborations program, we are encouraged by our partners’ response to NeXT Liquid Biopsy. NeXT Liquid Biopsy represents a new capability in the market and we look forward to working closely with our first customers. This is just the first step in Personalis’ liquid biopsy product portfolio and we are excited for further developments in this area."

NeXT Liquid Biopsy is immediately available for order.